Advertisement

Picture BCNP Consultants European Chemistry Partnering 2018 Ffm Germany 600x60px
Document › Details

Aldevron LLC. (7/9/13). "Press Release: Aldevron Part of 1.3M Euro Collaboration for a Bioactive Self-organising Vascular Graft". Fargo, ND.

Region Region Germany
Organisations Organisation Aldevron Freiburg GmbH
  Group Aldevron (Group)
  Organisation 2 VascuTrap project (Bioactive Self-organising Vascular Graft, BMBF, 201209–)
Products Product cardiovascular device
  Product 2 biomaterials
Person Person Thompson, John (Aldevron 201112 Managing Director Aldevron Freiburg GmbH)
     


VascuTrap: improved synthetic blood vessel bypasses for patients with coronary arterial diseases


Aldevron (Fargo, ND) announced today its participation in a joint research project partially funded by the German state (Bundesministerium für Bildung und Forschung) entitled "Bioactive self-organising vascular graft: VascuTrap" (started September 1, 2012) together with Aesculap AG, polyMaterials AG, Natural and Medical Sciences Institute of Tübingen University (NMI) and the University Hospital, Tübingen. The total volume of this project is 1.289 million EURO over three years.

Millions of patients worldwide suffer from coronary arterial diseases and in the USA alone, 1.5 million bypass operations are carried out per year to treat these diseases. Many patients require synthetic bypasses, the materials of which are however, thrombogenic leading to premature blockages. The overall goal of this VascuTrap project is to generate long-lasting synthetic blood vessel bypasses for patients suffering from coronary arterial diseases, but also as improvements for treatment of blockages in the aorta or in peripheral arteries. The idea is to coat these synthetic vessels with patient´s own endothelial cells, in vivo to avoid premature blockages and thereby prolong the life-span of these synthetic vessels.

"This has tremendous potential for developing more efficient forms of graft for coronary arterial diseases sufferers" said Dr John Thompson, Managing Director of Aldevron Freiburg. "This project will enable us to apply our core technology to develop antibodies with high specificity against cell surface marker molecules that will help prolong the life-span of synthetic blood vessel grafts."

Aldevron Freiburg´s role in this interdisciplinary project is to develop specific antibodies against a marker protein on the cell surface of the patient´s own progenitor endothelial stem cells that are responsible for building new blood vessels. The progenitor cells are found in small numbers in the circulation. The antibodies will be coated onto the interior surface of the synthetic bypass, in order to trap the circulating endothelial stem cells. These will then generate a patient-autologous blood vessel within the synthetic bypass, thereby disguising any thrombogenic influences and hopefully prolonging the life-span of such grafts. Aesculap AG is responsible for the development of new synthetic bypasses, polyMaterials AG will be responsible for attachment of the active antibodies generated by Aldevron Freiburg GmbH to the inner surface of these bypasses. The NMI is responsible for the in vitro testing and optimization of these coated synthetic blood vessels and the University Hospital Tübingen will be responsible for the pre-clinical testing and optimization for patients.


About Aldevron

Aldevron provides contract plasmid production, protein services, and custom antibody generation. With facilities in the U.S. and Europe for the past fifteen years, we are a global supplier to many biotech and pharmaceutical organizations for research, clinical, diagnostic and commercial applications. Whether adopting a client's protocol or developing a "Designed for You" approach, we deliver the highest-quality solutions on time and on budget with a focus on customer satisfaction.

Contact: John Thompson, Managing Director - Aldevron Freiburg GmbH, Waltershofener St. 17, 79111 Freiburg, Germany, +49 (0)761 45636-0, antibody@aldevron.com

###

Tags: blood passage bypass, Arterial disease, bioactive, VascuTrap, Antibody development


   
Record changed: 2017-04-02

Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA September 600x60px

To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture BIO Deutschland EBDC 2017 Heidelberg 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BCNP Consultants European Chemistry Partnering 2018 Ffm 120x180px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture BCNP Consultants European Chemistry Partnering 2018 Ffm 120x180px